135 related articles for article (PubMed ID: 10823364)
1. Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.
Marchetti A; Wang L; Magar R; Grossman HB; Lamm DL; Schellhammer PF; Erwin-Toth P
Clin Ther; 2000 Apr; 22(4):422-38. PubMed ID: 10823364
[TBL] [Abstract][Full Text] [Related]
2. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
[TBL] [Abstract][Full Text] [Related]
4. Intravesical valrubicin in the treatment of carcinoma in situ of the bladder.
Kuznetsov DD; Alsikafi NF; O'Connor RC; Steinberg GD
Expert Opin Pharmacother; 2001 Jun; 2(6):1009-13. PubMed ID: 11585003
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
Steinberg GD; Smith ND; Ryder K; Strangman NM; Slater SJ
Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
[TBL] [Abstract][Full Text] [Related]
6. Re: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.
Klotz L
J Urol; 2000 Nov; 164(5):1666. PubMed ID: 11025741
[No Abstract] [Full Text] [Related]
7. Valrubicin: an alternative to radical cystectomy for carcinoma in situ of the bladder.
Randall S
Urol Nurs; 2001 Feb; 21(1):30-1, 34-6. PubMed ID: 11998112
[TBL] [Abstract][Full Text] [Related]
8. Medical management of patients with refractory carcinoma in situ of the bladder.
Kim JC; Steinberg GD
Drugs Aging; 2001; 18(5):335-44. PubMed ID: 11392442
[TBL] [Abstract][Full Text] [Related]
9. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder.
Wymer KM; Sharma V; Saigal CS; Chamie K; Litwin MS; Packiam VT; Mossanen M; Pagliaro LC; Borah BJ; Boorjian SA
J Urol; 2021 May; 205(5):1326-1335. PubMed ID: 33347775
[TBL] [Abstract][Full Text] [Related]
11. Valrubicin in refractory non-muscle invasive bladder cancer.
Sharma P; Zargar-Shoshtari K; Sexton WJ
Expert Rev Anticancer Ther; 2015; 15(12):1379-87. PubMed ID: 26569509
[TBL] [Abstract][Full Text] [Related]
12. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.
Kulkarni GS; Alibhai SM; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Bayoumi AM
Cancer; 2009 Dec; 115(23):5450-9. PubMed ID: 19685529
[TBL] [Abstract][Full Text] [Related]
14. Valrubicin.
Onrust SV; Lamb HM
Drugs Aging; 1999 Jul; 15(1):69-75; discussion 76. PubMed ID: 10459733
[TBL] [Abstract][Full Text] [Related]
15. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer.
Patterson AL; Greenberg RE; Weems L; Bahnson R; Wajsman Z; Israel M; Sweatman T; Webber D; Gulfo J
Urology; 2000 Aug; 56(2):232-5. PubMed ID: 10925084
[TBL] [Abstract][Full Text] [Related]
17. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of carcinoma in situ of the urinary bladder].
Harada Y; Seguchi T; Nonomura N; Kojima Y; Miki T; Okuyama A
Nihon Hinyokika Gakkai Zasshi; 1998 Aug; 89(8):693-7. PubMed ID: 9780653
[TBL] [Abstract][Full Text] [Related]
19. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]